Bessemer Group’s BeOne Medicines Ltd ONC Stock Holding History

Bessemer Group’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-35	Closed	-$10K	–	2675
2026 Q1	$10K	Buy	+35	New	+$11.3K	﹤0.01%	2126
2025 Q4	–	Sell	-6	Closed	-$2K	–	2758
2025 Q3	$2K	Buy	+6	New	+$1.82K	﹤0.01%	2367
2022 Q2	–	Sell	-36	Closed	-$7K	–	2052
2022 Q1	$7K	Hold	36	–	–	﹤0.01%	1459
2021 Q4	$10K	Sell	36 -9	-20%	-$3.04K	﹤0.01%	1434
2021 Q3	$16K	Buy	45 +3	+7%	+$981	﹤0.01%	1283
2021 Q2	$14K	Sell	42 -92	-69%	-$30.5K	﹤0.01%	1289
2021 Q1	$47K	Sell	134 -25,214	-99%	-$8.35M	﹤0.01%	1028
2020 Q4	$6.55M	Sell	25,348 -13,947	-35%	-$3.84M	0.02%	235
2020 Q3	$11.3M	Buy	+39,295	New	+$9.24M	0.03%	198
2016 Q2	–	Sell	-1,183	Closed	-$35K	–	1471
2016 Q1	$35K	Buy	+1,183	New	+$33.5K	﹤0.01%	965

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bessemer Group's ONC Position: Q2 2026 in Review

Bessemer Group sold out of BeOne Medicines Ltd (ONC) in Q2 2026, closing a stake of 35 shares — an estimated $10K sold.

Bessemer Group first reported a position in ONC in Q1 2016 and held it in 10 quarters. The position peaked at $11.3M in Q3 2020. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Bessemer Group reported no remaining BeOne Medicines Ltd position as of Q2 2026 after selling out during the quarter.
Bessemer Group sold 35 BeOne Medicines Ltd shares in Q2 2026, an estimated $10K.
Bessemer Group first reported a position in BeOne Medicines Ltd in Q1 2016 and held it in 10 quarters.
Bessemer Group's BeOne Medicines Ltd position peaked at $11.3M in Q3 2020.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.